MRSN

Mersana Therapeutics (MRSN)

About Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Details

Daily high

$29.39

Daily low

$28.84

Price at open

$29.29

52 Week High

$40.88

52 Week Low

$5.21

Market cap

144.7M

Dividend yield

0.00%

Volume

85,361

Avg. volume

58,447

P/E ratio

-2.05

Mersana Therapeutics News